await clariti futur
lower estim reduc pt
await detail rx separ look
forward strateg updat sept view new
brand over-the-counter switch platform strategi encourag
lower estim cut revenu estim
management rang also
lower ep project management rang
assum management continu drive cost
effici enhanc margin compound-annual-growth-rate stand revenue
ep note incorpor potenti dis-synergi
possibl rx busi separ project new vs old vs
reduc pt cut pt old ep
new ep target price-to-earnings discount mean
premium vs gener group mean ep due
durabl franchis lower leverag risk reward look forward
septemb
await detail separ includ quantif dis-synergi
plan separ rx busi state board consid
value-enhanc option includ sale merger tax-effici separ
sharehold rx separ expect complet
call management state meaning impact separ
compani detail process minim implic
individu busi howev recal june investor confer
ask potenti rx separ management state go-to market
everyth els chc busi make -- design anda
way rx chca plan integr qualiti system
integr think see tremend valu portfolio --
segment structur point
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
brand over-the-counter switch strategi offer new avenu help drive us consum
growth nasonex repres first leverag platform execut
brand over-the-counter switch management convey specif timelin bring over-the-counter
nasonex market faster typic
timelin think theoret possibl merck data packag could
allow file over-the-counter nasonex next year includ
placehold project initi over-the-counter nasonex sale model
importantli see potenti partner choic rx
manufactur consid certain brand over-the-counter switch futur
expans due cost cut solid
revenue ep
price target base ep target price-to-earnings
discount mean premium vs gener specialti
pharma group mean ep due busi mix less leverag
pipelin drive earn upsid multipl expans new launch drive
ep multipl increas consum segment perform better
deliv result line expect growth prospect
remain cloudi manag execut well improv chci
segment perform return modest growth rel
new launch disappoint pressur worsen us consum rx declin
new launch delay competit pressur worsen ep
north american store-brand
counter medicin adj op incom
intern consum over-the-counter adj
op incom franchis omega
management work turn around
nich prescript rx gener
adj op incom leader gener topic
limit competit gener nich
quarterli result guidanc updat
gproair launch
risk achiev price
new product launch delay
exhibit us spec brand gx comp sheet
us specialti brand gener
price
spec brand gx mean
spec brand gx median
price
valuat methodolog risk associ price target rate
recommend referenc research report pleas contact client support
follow us/canada hong kong latin
sydney tokyo altern may contact
invest repres morgan stanley research broadway attent
exhibit incom statement margin analysi valuat
sg sale
 sale
exhibit balanc sheet
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
